A molecule called Alda-1 can repair Aldehyde dehydrogenase 2 (ALDH2), an often defective alcohol metabolism enzyme that affects an estimated 1 billion people worldwide, according to research published Jan. 10 in the advance online edition of Nature Structural and Molecular Biology. The findings suggest the possibility of a treatment to reduce the health problems associated with the enzyme defect.
After alcohol is consumed, it is metabolized into acetaldehyde, a toxic chemical that causes DNA damage. Aldehyde dehydrogenase 2 (ALDH2) is the main enzyme responsible for breaking down acetaldehyde into acetate, a nontoxic metabolite in the body. It also removes other toxic aldehydes that can accumulate in the body.
About 40 percent of the East Asian population, and many people of East Asian descent throughout the world, carry a genetic mutation that produces an inactive form of ALDH2. When individuals with the ALDH2 mutation drink alcohol, acetaldehyde accumulates in the body, resulting in facial flushing, nausea, and rapid heartbeat. In addition to its link to increased cancer risk, the inactive form of ALDH2 also reduces the effectiveness of nitroglycerin. Nitroglycerin is a drug to treat angina, chest pain that occurs when the heart doesn't get enough oxygen-rich blood.
In a series of experiments that examined the interaction between Alda-1 and the defective ALDH2 enzyme, researchers found that Alda-1 restored the structure of the inactive enzyme. The normal, active form of ALDH2 creates a catalytic tunnel, a space within the enzyme in which acetaldehyde is metabolized, explained Dr. Hurley. In the defective enzyme, the tunnel does not function properly. Alda-1 binds to the defective enzyme in a way that effectively reopens the catalytic tunnel and thus allows the enzyme to metabolize acetaldehyde
"The manner in which Alda-1 binds to the structure of ALDH2 provides us with powerful insight into the relationships between activators and inhibitors of this crucial detoxifying enzyme," says Dr. Hurley. "This insight will lead to the modification of Alda-1 to improve its potency, and also opens up the possibility of designing new analogs that can selectively affect the metabolism of other molecules that are detoxified by aldehyde dehydrogenase."
"This intriguing finding could have broad public health implications," said NIAAA Acting Director Kenneth R. Warren, Ph.D. "We look forward to further research aimed at translating these laboratory discoveries into possible treatments for people."
Citation: Perez-Miller et al., 'Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant', Nature Structural and Molecular Biology Online, January 2010; doi:10.1038/nsmb.1737
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Your Probiotic Probably Has Gluten
- Bang !! 13 TeV - The Highest Energy Ever Achieved By Mankind ?!
- 'Natural' Sounds Improve May Improve Office Mood And Productivity
- The Case Of The Missing Booze: Brits Drink 12 Million More Bottles Per Week Than Previous Estimates
- Mummy Madness In The Anatomical Record - All Open Access
- Mystery Of Morgellons - Disease Or Delusion - Scientific Hypothesis Of Connection With Lyme Disease
- Will We Soon Have A 2-D Liquid?
- "its contents truly incredible nice and interesting, and we liked it very much. we also await a..."
- "Here's one good answer to the question of your title: http://rt.com/news/261673-india-gmo..."
- "I'm fine, don't have Morgellons or chronic lyme disease, and thinking about the condition doesn't..."
- "[t]he only thing that can set us right is a katalepsis, a seizure by grace, something transformative..."
- "Well, Soon after having sent my previous comment I got a message from Neil Sloane that he had published..."
- Savannahs slow climate change
- Sudden onset of ice loss in Antarctica detected
- Proton therapy has fewer side effects in esophageal cancer patients
- Mood instability common to mental health disorders and associated with poor outcomes
- Depression associated with 5-fold increase in mortality risk for heart failure patients